Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Infections, Human Immunodeficiency Virus and Tuberculosis
Interventions: GSK1349572, Placebo, Iohexol Injection, Para-aminohippurate infusion; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: Abemaciclib, Placebo, Loperamide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Daytona Beach, Florida • Evansville, Indiana

Conditions: Dermatitis, Atopic, Pruritus, Dermatitis Eczema
Interventions: ASN008 TG, Placebo TG; Drug
Lead sponsor: Asana BioSciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more

Conditions: Chronic Kidney Disease
Interventions: MEDI8367, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hematopoietic Syndrome Due to Acute Radiation Syndrome
Interventions: HemaMax, Placebo; Biological · Drug
Lead sponsor: Neumedicines Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more

Conditions: Dry Eye
Interventions: EBI-005-1, EBI-005-1 Placebo; Drug
Lead sponsor: Eleven Biotherapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: HM10760A or placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: US, California

Conditions: Age-related Macular Degeneration
Interventions: QA102, Placebo; Drug
Lead sponsor: Smilebiotek Zhuhai Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: ATH-1105, Placebo; Drug
Lead sponsor: LeonaBio; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pediculosis
Interventions: Ha44, Ha44 Placebo, Moxifloxacin Placebo, Moxifloxacin; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Healthy Volunteers
Interventions: ATH-1020, Placebo; Drug
Lead sponsor: LeonaBio; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Phase 1 First-in-human Study Involving Healthy Subjects
Interventions: TNX-1500, Placebo: USP 0.9% sterile saline for injection, Keyhole Limpet Hemocyanin (KLH); Drug · Biological
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Participants
Interventions: BBT-877 single dose, Placebo single dose; Drug
Lead sponsor: Bridge Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: AZD5847, Placebo to AZD5847; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: VBP15, Placebo; Drug
Lead sponsor: ReveraGen BioPharma, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Thyroid Eye Disease
Interventions: AMG 732, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Little Rock, Arkansas • Newport Beach, California • Jacksonville, Florida + 9 more

Conditions: Anthrax
Interventions: Px563L, RPA563, or placebo; Biological
Lead sponsor: Pfenex, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Otherwise Healthy Overweight or Obese
Interventions: PHP-303, Placebo; Drug · Other
Lead sponsor: pH Pharma; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Alzheimer's Disease
Interventions: NGP 555; Drug
Lead sponsor: NeuroGenetic Pharmaceuticals Inc; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Volunteers
Interventions: TAK-105-a, TAK-105-a Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Tempe, Arizona • Las Vegas, Nevada • Austin, Texas

Conditions: Hematopoietic Syndrome Due to Acute Radiation Syndrome
Interventions: HemaMax, Placebo; Biological · Drug
Lead sponsor: Neumedicines Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Subjects
Interventions: A: pacritinib, B: Placebo, C: moxifloxacin; Drug · Other
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Anthocyanins
Interventions: ACRB, Placebo; Dietary Supplement · Other
Lead sponsor: Pharmanex; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Davis, California

Conditions: Healthy Volunteers
Interventions: Ziresovir 125 mg, Ziresovir 500 mg, Placebo, Moxifloxacin hydrochloride tablet 400 mg; Drug
Lead sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Glendale, California

Search by objective public record fields.

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

A Study of Abemaciclib in Healthy Participants

Study to Evaluate ASN008 Topical Gel (TG)

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease

Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome

Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects

A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105

Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers

Safety, Tolerability, and Pharmacokinetics Study of ATH-1020

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male

Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers

A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)

A Study of TAK-105 in Healthy Adults

Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure

To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects

Inflammatory and Metabolic Responses to Long-term Dietary Supplementation With Anthocyanin-rich Blend

Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects